Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-up, and Treatment for Patients Till the Age of 18 Years

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2012 Oct 31

PMID 23109216

Citations 210

Authors

Riccardo Haupt

Milen Minkov

Itziar Astigarraga

Eva Schafer

Vasanta Nanduri

Rima Jubran

R Maarten Egeler

Gritta Janka

Dragan Micic

Carlos Rodriguez-Galindo

Stefaan Van Gool

Johannes Visser

Sheila Weitzman

Jean Donadieu

Affiliations

Soon will be listed here.

Abstract

These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who participated in national or international studies and in peer reviewed publications. Existing guidelines were reviewed and changed where new evidence was available in the literature up to 2012. Data and publications have been ranked according to evidence based medicine and when there was a lack of published data, consensus between experts was sought. Guidelines for diagnosis, initial clinical work-up, and treatment and long-term follow-up of LCH patients are presented.

Citing Articles

Langerhans Cell Histiocytosis and Other Histiocytic Lesions.

McKinney R, Wang G Head Neck Pathol. 2025; 19(1):26.

PMID: 39998733 PMC: 11861498. DOI: 10.1007/s12105-025-01766-2.

Advances in allogeneic hematopoietic stem cell transplantation for Langerhans cell histiocytosis in children.

Meng G, Feng S, Wang Y Front Immunol. 2025; 16:1345855.

PMID: 39935470 PMC: 11810885. DOI: 10.3389/fimmu.2025.1345855.

Unraveling Histiocytic Disorders: Two Cases From Resource-Limited Settings.

Elbahoty M, Soror N, Elnaggar M, Gad S, Eldowik Y, Halwag D Cureus. 2025; 16(12):e76622.

PMID: 39881909 PMC: 11776764. DOI: 10.7759/cureus.76622.

Langerhans cell histiocytosis in children: the value of ultrasound in diagnosis and follow-up.

Yang J, Huang X, Bao Z, Xu J, Huang H, Huang H BMC Med Imaging. 2025; 25(1):29.

PMID: 39881244 PMC: 11776198. DOI: 10.1186/s12880-025-01563-x.

[Ga]Ga‑FAPI PET/CT in the evaluation of Langerhans cell histiocytosis: comparison with [F]FDG PET/CT.

Zhang W, Wu Y, Guo L, Li X, Shen G Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39833506 DOI: 10.1007/s00259-025-07097-2.

References

Phillips M, Allen C, Gerson P, McClain K . Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2008; 52(1):97-101. DOI: 10.1002/pbc.21782. View

. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group. Arch Dis Child. 1996; 75(1):17-24. PMC: 1511663. DOI: 10.1136/adc.75.1.17. View

Kenney L, Bradeen H, Kadan-Lottick N, Diller L, Homans A, Schwartz C . The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2011; 57(6):1062-6. DOI: 10.1002/pbc.22924. View

Nanduri V, Pritchard J, Levitt G, Glaser A . Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer. 2006; 42(15):2563-9. DOI: 10.1016/j.ejca.2006.05.031. View

Satoh T, Smith A, Sarde A, Lu H, Mian S, Mian S . B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One. 2012; 7(4):e33891. PMC: 3323620. DOI: 10.1371/journal.pone.0033891. View

Tazi A, Soler P, HANCE A . Adult pulmonary Langerhans' cell histiocytosis. Thorax. 2000; 55(5):405-16. PMC: 1745752. DOI: 10.1136/thorax.55.5.405. View

Egeler R, THOMPSON Jr R, VOUTE P, Nesbit Jr M . Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. J Pediatr Orthop. 1992; 12(6):811-4. DOI: 10.1097/01241398-199211000-00021. View

Buchler T, cervinek L, Belohlavek O, Kantorova I, Mechl M, Nebesky T . Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer. 2004; 44(3):286-8. DOI: 10.1002/pbc.20175. View

Chikwava K, Jaffe R . Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol. 2005; 7(6):607-14. DOI: 10.1007/s10024-004-3027-z. View

10.

Raney Jr R, DAngio G . Langerhans' cell histiocytosis (histiocytosis X): experience at the Children's Hospital of Philadelphia, 1970-1984. Med Pediatr Oncol. 1989; 17(1):20-8. DOI: 10.1002/mpo.2950170106. View

11.

Curry H, Parkes S, Powell J, Mann J . Caring for survivors of childhood cancers: the size of the problem. Eur J Cancer. 2006; 42(4):501-8. DOI: 10.1016/j.ejca.2005.11.003. View

12.

Badalian-Very G, Vergilio J, Degar B, Macconaill L, Brandner B, Calicchio M . Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010; 116(11):1919-23. PMC: 3173987. DOI: 10.1182/blood-2010-04-279083. View

13.

Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H . Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002; 39(6):581-5. DOI: 10.1002/mpo.10166. View

14.

Galluzzo M, Braier J, Rosenzweig S, Garcia de Davila M, Rosso D . Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis. Pediatr Dev Pathol. 2009; 13(2):101-6. PMC: 3740343. DOI: 10.2350/09-05-0651-OA.1. View

15.

. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000; 85(11):3990-3. DOI: 10.1210/jcem.85.11.6984. View

16.

Steen A, Steen K, Bauer R, Bieber T . Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001; 145(1):137-40. DOI: 10.1046/j.1365-2133.2001.04298.x. View

17.

Dimentberg R, Brown K . Diagnostic evaluation of patients with histiocytosis X. J Pediatr Orthop. 1990; 10(6):733-41. DOI: 10.1097/01241398-199011000-00006. View

18.

Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M . Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005; 41(17):2682-9. DOI: 10.1016/j.ejca.2005.02.007. View

19.

Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y . Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 2000; 12(1):71-81. DOI: 10.1016/s1074-7613(00)80160-0. View

20.

Womer R, Anunciato K, Chehrenama M . Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol. 1995; 25(2):70-3. DOI: 10.1002/mpo.2950250204. View